Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Nuwellis (CHFS) Competitors

Nuwellis logo

CHFS vs. NRXS, QTI, VRAYQ, VIVE, ELMD, TARA, AVTX, ANIK, OKYO, and AGEN

Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include NeurAxis (NRXS), QT Imaging (QTI), ViewRay (VRAYQ), Viveve Medical (VIVE), Electromed (ELMD), Protara Therapeutics (TARA), Avalo Therapeutics (AVTX), Anika Therapeutics (ANIK), OKYO Pharma (OKYO), and Agenus (AGEN). These companies are all part of the "medical" sector.

Nuwellis vs. Its Competitors

NeurAxis (NASDAQ:NRXS) and Nuwellis (NASDAQ:CHFS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

In the previous week, NeurAxis had 5 more articles in the media than Nuwellis. MarketBeat recorded 5 mentions for NeurAxis and 0 mentions for Nuwellis. NeurAxis' average media sentiment score of 0.26 beat Nuwellis' score of 0.00 indicating that NeurAxis is being referred to more favorably in the media.

Company Overall Sentiment
NeurAxis Neutral
Nuwellis Neutral

NeurAxis has a beta of 3.1, suggesting that its stock price is 210% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

NeurAxis presently has a consensus target price of $7.00, suggesting a potential upside of 190.46%. Given NeurAxis' stronger consensus rating and higher possible upside, equities research analysts clearly believe NeurAxis is more favorable than Nuwellis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Nuwellis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

NeurAxis has higher earnings, but lower revenue than Nuwellis. NeurAxis is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeurAxis$2.93M5.93-$14.63M-$0.99-2.43
Nuwellis$5.51M6.07-$18.11M-$279.28-0.02

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 65.1% of Nuwellis shares are held by institutional investors. 26.4% of NeurAxis shares are held by company insiders. Comparatively, 0.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nuwellis has a net margin of -254.26% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Nuwellis' return on equity.

Company Net Margins Return on Equity Return on Assets
NeurAxis-492.76% N/A -641.25%
Nuwellis -254.26%-173.61%-131.01%

Summary

NeurAxis beats Nuwellis on 10 of the 16 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CHFS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHFS vs. The Competition

MetricNuwellisElectromedical Equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$33.45M$28.58M$5.67B$9.82B
Dividend YieldN/AN/A3.79%4.07%
P/E Ratio-0.112.8230.5825.12
Price / Sales6.07208.67460.38114.01
Price / CashN/A41.3637.4059.05
Price / Book0.432.129.096.18
Net Income-$18.11M-$2.66M$3.25B$264.89M

Nuwellis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHFS
Nuwellis
N/A$5.54
-1.8%
N/A+148.5%$33.45M$5.51M-0.1166Gap Down
NRXS
NeurAxis
2.8374 of 5 stars
$2.49
+2.5%
$7.00
+181.1%
-23.1%$17.97M$2.93M-1.3519Short Interest ↑
QTI
QT Imaging
N/A$1.90
+2.7%
N/A+321.9%$10.72M$4.00M0.00N/AGap Down
VRAYQ
ViewRay
N/AN/AN/AN/A$18K$102.21M0.00300High Trading Volume
VIVE
Viveve Medical
N/A$0.00
flat
N/A-66.7%$1K$6.83M0.0070
ELMD
Electromed
1.3271 of 5 stars
$19.34
+1.0%
$33.50
+73.2%
+31.3%$162.19M$61.44M25.79160
TARA
Protara Therapeutics
2.1618 of 5 stars
$3.07
-1.0%
$19.60
+538.4%
+47.8%$119.60MN/A-1.9030News Coverage
Earnings Report
Analyst Revision
AVTX
Avalo Therapeutics
3.4979 of 5 stars
$9.36
+3.9%
$30.00
+220.5%
-2.6%$118.44M$440K0.0040News Coverage
Analyst Forecast
Short Interest ↓
Gap Up
ANIK
Anika Therapeutics
4.3692 of 5 stars
$8.72
+6.2%
$18.00
+106.4%
-65.4%$118.37M$119.91M-2.10300
OKYO
OKYO Pharma
3.1509 of 5 stars
$2.96
-5.1%
$7.00
+136.5%
+170.4%$117.35MN/A0.007Gap Up
AGEN
Agenus
4.0066 of 5 stars
$4.81
+12.6%
$16.33
+239.6%
-10.4%$117.07M$103.46M-0.67440News Coverage
Earnings Report
Analyst Upgrade
Analyst Revision
Gap Up

Related Companies and Tools


This page (NASDAQ:CHFS) was last updated on 8/16/2025 by MarketBeat.com Staff
From Our Partners